AN2 Therapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1800 El Camino Real Ste 100, Menlo Park,...Phone Number
(650) 331-9090Website
www.an2therapeutics.comRevenue
-Stock Symbol
ANTXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About AN2 Therapeutics
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing boron-based drug candidates for infectious disease, hematology, and oncology. The company uses its chemistry platform to discover and advance novel therapies through preclinical research, clinical trials, and pipeline development aimed at serious unmet medical needs globallyExplore more
AN2 Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AN2 Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on AN2 Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at AN2 Therapeutics
Click to see if AN2 Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when AN2 Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Check out if AN2 Therapeutics is spiking on competitors!
Check if AN2 Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
AN2 Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once AN2 Therapeutics has new funding data
Recommended Actions
Find VP level buyers at AN2 Therapeutics
Find 3 more new buyers
Compare Similar Companies to AN2 Therapeutics
Compare insights from companies similar to AN2 Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
AN2 Therapeutics financials insights
Gather financial insights about AN2 Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$12M
2022
Series B
$80M
Stock Offering
$69M
2026
Private Equity
$40M
AN2 Therapeutics Tech Stack
A closer look at the technologies used by AN2 Therapeutics
Most Recent Scoops
Person-Based
Events
Person-Based
Events
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Events
AN2 Therapeutics News & Media
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company will present a poster highlighting the preclinical activity of epetraborole against M. abscessus on Thursday, May 29, 2025 at the Nontuberculous Mycobacteria Conference to be held May 27-30, 2025 at Colorado State University. It is estimated thatAN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first quarter ended March 31, 2025. “As we look ahead to the remainder of 2025, we are poised to advance our pipeline leveraging our boron chemistry platform, which has the potential to address serious unmet needs of patients. We have highAN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced topline results from the Phase 3 portion of the EBO-301 study evaluating epetraborole on top of an optimized background regimen (EBO+OBR) in treatment-refractory MAC lung disease. The truncated Phase 3 portion of the study did not meet its primary endpoint on imprAN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from May 7-8, 2025 in New York. Details of the event is as follows: Citizens JMP Life Sciences Conference Eric
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AN2 Therapeutics
Sign Up For FreeTo access detailed company insights
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing boron-based drug candidates for infectious disease, hematology, and oncology. The company uses its chemistry platform to discover and advance novel therapies through preclinical research, clinical trials, and pipeline development aimed at serious unmet medical needs globally... Read More
